PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19240170-1 2009 PURPOSE: This study aimed to test the hypothesis that elevated expression of antiapoptotic Bcl-2 family proteins predicts a poor therapeutic response of oropharyngeal squamous cell carcinoma (OPSCC) to concurrent platinum-based chemoradiation therapy. Platinum 213-221 BCL2 apoptosis regulator Homo sapiens 91-96 19240170-8 2009 CONCLUSIONS: Immunohistochemical assessment of Bcl-2 in pretreatment biopsy specimens can predict response of advanced OPSCC to concurrent platinum-based chemoradiation. Platinum 139-147 BCL2 apoptosis regulator Homo sapiens 47-52 19516889-10 2009 The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis. Platinum 119-127 BCL2 apoptosis regulator Homo sapiens 75-80 15072449-5 2004 In particular, as demonstrated by densitometric analysis, after exposure to both platinum compounds the total amount of the anti-apoptotic protein Bcl-2 was significantly reduced. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 147-152 17160181-4 2007 Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre. Platinum 195-203 BCL2 apoptosis regulator Homo sapiens 108-112 10807947-5 2000 A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation. Platinum 153-161 BCL2 apoptosis regulator Homo sapiens 286-291 12644821-12 2003 BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer patients treated with platinum-based chemotherapy. Platinum 102-110 BCL2 apoptosis regulator Homo sapiens 0-5 34794242-0 2021 The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways. Platinum 25-27 BCL2 apoptosis regulator Homo sapiens 118-123 9891541-0 1998 p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Platinum 89-97 BCL2 apoptosis regulator Homo sapiens 8-13 34583845-1 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 40-45 34293698-0 2021 Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 168-172 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Platinum 29-37 BCL2 apoptosis regulator Homo sapiens 324-328 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Platinum 93-101 BCL2 apoptosis regulator Homo sapiens 324-328 33153817-18 2021 CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments. Platinum 177-185 BCL2 apoptosis regulator Homo sapiens 65-70 33153817-0 2021 Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Platinum 81-89 BCL2 apoptosis regulator Homo sapiens 40-45 35412302-5 2022 The introduction of iodine not only enhances the CT imaging signal with a much lower dose of Pt but also overcomes the resistance of tumor cells to Pt-containing nanomedicine by inhibiting the expression of Bcl-2. Platinum 148-150 BCL2 apoptosis regulator Homo sapiens 207-212 30774376-0 2019 Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. Platinum 10-18 BCL2 apoptosis regulator Homo sapiens 85-90 33744756-6 2021 Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells. Platinum 0-2 BCL2 apoptosis regulator Homo sapiens 35-40 32309901-0 2020 Platinum nanoparticles induced genotoxicity and apoptotic activity in human normal and cancer hepatic cells via oxidative stress-mediated Bax/Bcl-2 and caspase-3 expression. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 142-147 32703189-14 2020 Exposure to PT resulted in the downregulation of anti-apoptotic proteins (Bcl2, BclxL, XIAP) and alteration in Cyclins expression. Platinum 12-14 BCL2 apoptosis regulator Homo sapiens 74-78 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 191-199 BCL2 apoptosis regulator Homo sapiens 19-24 28166401-4 2017 After 3 h of exposure to these platinum(II) agents, >50% of BCL-2 siRNA transcripts were platinated and unable to effectively suppress mRNA levels. Platinum 31-39 BCL2 apoptosis regulator Homo sapiens 63-68 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 35-43 BCL2 apoptosis regulator Homo sapiens 109-114 28166401-9 2017 Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to <10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by >5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line). Platinum 191-199 BCL2 apoptosis regulator Homo sapiens 19-24 23455184-3 2013 The major aim of this study was to further define the expression pattern and the prognostic role of Bcl-2 together with BAG-1, BAG-3, and BAG-4 proteins in EOC patients receiving platinum/taxane-based chemotherapy. Platinum 179-187 BCL2 apoptosis regulator Homo sapiens 100-105 27822420-0 2016 Genetic variants of BCL2 gene predict clinical outcomes of non-small-cell lung cancer patients treated with platinum-based chemotherapy in a Chinese population. Platinum 108-116 BCL2 apoptosis regulator Homo sapiens 20-24 27822420-1 2016 Platinum agents induce cancer cell death through BCL2-dependent intrinsic apoptotic pathway and are commonly used as anti-tumor drug. Platinum 0-8 BCL2 apoptosis regulator Homo sapiens 49-53 27822420-2 2016 In this study, we evaluated whether single nucleotide polymorphism (SNPs) of BCL2 can affect the overall survival (OS) and progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Platinum 215-223 BCL2 apoptosis regulator Homo sapiens 77-81 27822420-3 2016 We genotyped 48 SNPs of BCL2 gene by Illumina Custom Designed Chip in 972 advanced NSCLC patients treated with platinum-based chemotherapy. Platinum 111-119 BCL2 apoptosis regulator Homo sapiens 24-28 27822420-10 2016 To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies. Platinum 72-80 BCL2 apoptosis regulator Homo sapiens 30-34 26893680-0 2016 Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer. Platinum 52-60 BCL2 apoptosis regulator Homo sapiens 8-12 27062783-5 2016 RESULTS: Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients (P < 0.05). Platinum 9-17 BCL2 apoptosis regulator Homo sapiens 99-104 27062783-7 2016 CONCLUSION: MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis. Platinum 51-59 BCL2 apoptosis regulator Homo sapiens 178-183 26656462-0 2015 Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy. Platinum 121-129 BCL2 apoptosis regulator Homo sapiens 17-21 26656462-5 2015 The data from the current study provide evidence that BCL2-938C>A and BAX-248G>A polymorphisms may be useful in predicting clinical outcomes of patients with advanced inoperable NSCLC to platinum-based chemotherapy. Platinum 193-201 BCL2 apoptosis regulator Homo sapiens 54-58 24560445-7 2014 In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2). Platinum 23-31 BCL2 apoptosis regulator Homo sapiens 103-107